2nd LNP Immunogenicity & Toxicity Summit
Back for its second iteration, the LNP Immunogenicity & Toxicity Summit (December 11-13, 2023 | Boston) will bring together 100+ PKPD, Immunology, Safety, Toxicology experts from biopharma and academia to share best practice and address the next wave of challenges. With a unique agenda designed specifically on the hottest topics requested from the industry experts, this is your opportunity to analyze your LNP with precise PKPD, biodistribution, immune response for applications in gtx therapy, vaccination and much more. You will leave with a deeper understanding of the innovative work going on to developing robust safety profiles and deepen your knowledge on novel LNP based therapeutics, as well as multiple case studies which outline strategic and technical conducts.
Snapshot of expert speakers:
- Sophie Tourdot, Immunogenicity Sciences Lead, Pfizer
- Jan Diekmann, Senior Director Non – Clinical Safety, BioNTech
- Joanna Grudzinska, Goebel DMPK Project Lead, Bayer
- Maria-Dolores Vasquez-Abad, Team Lead, Clinical Immunogenicity & Medicine, Pfizer
- Amy Rosenberg, Senior Director of Immunology & Protein Therapeutics, Epivax (Former FDA)
